Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) EPS (Weighted Average and Diluted) (2016 - 2025)

Lisata Therapeutics (LSTA) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.49 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Weighted Average and Diluted) rose 16.95% year-over-year to -$0.49, compared with a TTM value of -$2.13 through Sep 2025, up 15.14%, and an annual FY2024 reading of -$2.4, up 6.98% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.49 for Q3 2025 at Lisata Therapeutics, up from -$0.54 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.49 in Q3 2025 and bottomed at -$0.77 in Q1 2023.
  • Average EPS (Weighted Average and Diluted) over 3 years is -$0.6, with a median of -$0.59 recorded in 2024.
  • The sharpest move saw EPS (Weighted Average and Diluted) decreased 19.61% in 2024, then grew 16.95% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.66 in 2023, then grew by 16.67% to -$0.55 in 2024, then grew by 10.91% to -$0.49 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for LSTA at -$0.49 in Q3 2025, -$0.54 in Q2 2025, and -$0.55 in Q1 2025.